Patent intelligence · US
US 7250182
Medicament containing Epimedium extract for treatment of prostatic hyperplasia and prostatitis
Medicament containing Epimedium extract for treatment of prostatic hyperplasia and prostatitis
Patent details — US 7250182
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 31, 2007
- Expiration
- Jul 26, 2027
- Claims
- 6
- CPC classes
- A61K, A61K36/00, A61K36/258, A61K36/296
Quick answer
US 7250182 (Medicament containing Epimedium extract for treatment of prostatic hyperplasia and prostatitis) is held by Bright Future Pharmaceutical Laboratories. Status: granted. Granted Jul 31, 2007. Expires Jul 26, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K36/00, A61K36/258, A61K36/296, A61K36/481, A61K36/756
More from Bright Future Pharmaceutical Laboratories
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 7250182?
US 7250182 (Medicament containing Epimedium extract for treatment of prostatic hyperplasia and prostatitis) is held by Bright Future Pharmaceutical Laboratories. Status: granted. Granted Jul 31, 2007. Expires Jul 26, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7250182?
Bright Future Pharmaceutical Laboratories is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 7250182 expire?
Our index shows an expiration date of Jul 26, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.